

Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

14th February 2022

Corporate Relationship Department M/s. BSE Limited Dalal Street, Fort <u>Mumbai 400 001.</u> Scrip Code: **524816** Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) <u>Mumbai 400 051.</u> Scrip Code: NATCOPHARM

Dear Sir,

Sub:- Outcome of Board Meeting

Further to our intimation letter dated 5th February, 2022, we would like to inform you that the Board of Directors of the Company at their meeting held on today have approved the following along with other items of business:

- Please find enclosed unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2021 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time ("Listing Regulations") along with Limited Review Report of the Statutory Auditors.
- 2. Declared 3rd interim dividend of Rs.2/- (Rupees one only) each per Equity share of Rs.2/- (Rupees two only) each for the financial year 2021-22 (which is 100% on the nominal value of the equity share). The date for taking on record of its shareholders eligible for the purpose of payment of third interim dividend i.e. record date is fixed as Friday, the 25th February 2022. The payment of said interim dividend will start from 4th March 2022.
- 3. Sri G S Murthy, Independent Director of the Company has been appointed as Chairman of the Company with effect from 1st April 2022.
- 4. Appointed / Re-appointed the following working Directors of the Company for a period of two year from 1st April 2022 to 31st March 2024 subject to the approval of the members of the Company by way of Postal Ballot. Brief profile of the below mentioned Directors is enclosed as annexure :

Name of the Director	DIN Number	Designation		
Sri V C Nannapaneni	00183315	Managing Director		
Sri Rajeev Nannapaneni	00183872	Director & CEO		
Sri P S R K Prasad 07011140 Director & Executive Vice		Director & Executive Vice President Corp Engineering Services		
Dr. D Linga Rao	07088404	Director & President (Technical Affairs)		

- Approved the Postal Ballot notice for seeking consent of the Shareholders for appointment/reappointment of Sri V.C. Nannapaneni, Managing Director, Sri Rajeev Nannapaneni, Chief Executive Officer, Sri P.S.R.K. Prasad, Director and Executive Vice President (Corporate Engineering Services)
- and Dr. D. Linga Rao, Director and President (Tech. affairs) for a period of two (2) years i.e., from 1st April 2022 to 31st March 2024.

MANerazew





Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

--:2--

- Sri Sridhar Sankararaman, Non-Executive Non Independent Director of the Company has resigned from the Directorship of the company with effect from 15th February, 2022 due to his professional obligations and other pre occupations.
- 7. The Board of Directors had reconstituted the following Committees of the Directors of the company with effect from 15th February 2022:

Audit Committee

SI.	Name of the Director
No.	
1	Sri G.S. Murthy, Independent Director
2	Sri T. V. Rao, Independent Director
3	Sri D. G. Prasad, Independent Director
4	Dr. M.U.R. Naidu, Independent Director

Nomination and Remuneration Committee

SI. No.	Name of the Director
1	Sri G.S. Murthy, Independent Director
2	Dr. M.U.R. Naidu, Independent Director
3	Sri T. V. Rao, Independent Director

We hereby confirm that all the above-mentioned Appointed / Re-appointed Directors are not debarred from holding the office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such authority.

Please find attached herewith the Press Release in this regard.

We are also updating the financial results of the company on our website.

This is for your information and records.

Meeting commenced at 11.30 a.m. and concluded at 4.30 p.m.

Thanking you

Yours faithfully For NATCO Pharma Limited

un

M Adinarayana ['] Company Secretary & Vice President (Legal & Corp Affairs)

Encl: as above



NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034. Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

CMENT OF INVITED CONCOUNTED FINANCIAL DESIDER FOR THE CONCERNMENT OF THE CONCERNMENT.

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2021	
--	--

			Quarter ended		Nine Mon	Nine Months ended	
S.No.	Particulars	31 December 2021	30 September 2021	31 December 2020	31 December 2021 31 December 2020		Year ended 31 March 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
			e initiativa	Chauteu	Chauditeu	Unaudited	Auditeu
	Income						
1	Revenue from operations (refer note 5)	5,605	3,772	3,552	13,480	17,208	20,53
2	Other income	302	380	308	852	752	1,03
3	Total income (1+2)	5,907	4,152	3,860	14,332	17,960	21,5
4	Expenses	111 - 11 - 11 - 11 - 11 - 11 - 11 - 11					
	Cost of materials consumed	1,006	1,156	756	3,261	2,836	3,7
	Purchases of stock-in-trade	56	127	322	260	1,836	1,8
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(132)	(358)	(247)	(875)	(103)	(4
	Employee benefits expense	1,182	1,092	1,014	3,355	2 202	4,1
	Finance costs	50	40	34	3,333	3,203 98	4,1
	Depreciation and amortisation expense	360	347	298	1,045	865	1,1
	Other expenses	2,475	1,050	882	4,658	4,136	5,1
	Total expenses	4,997	3,454	3,059	11,814	12,871	15,7
5	Profit before exceptional items and tax (3-4)	910	698	801	2,518	5,089	5,7
	Exceptional items	910	098	801	2,518	5,089	5,1
	Profit before tax (5-6)	910	698	801	2,518	5,089	5,1
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0,0	001	2,510	5,005	5,1
8	Tax expense						
	(i) Current tax	167	161	77	484	1,220	1,4
	(ii) Income-tax for earlier years		•	•	-	-	10
	(iii) Deferred tax (credit)/ charge (refer note 6)	(61)	(114)	90	(171)	(25)	(
	Total tax expense	106	47	167	313	1,195	1,
9	Profit for the period/year (7-8)	804	651	634	2,205	3,894	4,
0	Other comprehensive income (net of tax)						
	A. Items that will not be reclassified subsequently to profit or						
	loss:						
	Remeasurement of defined benefit plans	(2)	(2)	(20)	(6)	(59)	
	Net gains / (losses) from investments in equity instruments						
	designated at Fair value through other comprehensive income	335	(24)	26	411	136	
	(FVTOCI)						
	Income-tax relating to items that will not be reclassified to profit	(29)	3	(1)	(36)	(13)	
	or loss	. ,		(Sec. 1)			
		304	(23)	5	369	64	
	B. Items that will be reclassified subsequently to profit or loss:						
						-24/2284	
	Exchange differences on translation of foreign operations	(26)	(45)	36	(91)	(47)	
	× .	(26)	(45)	36	(91)	(47)	
	Total other comprehensive income (net of tax) (A+B)	278	(68)	41	278	17	
	Total other comprehensive mediae (act of tax) (A+D)						
1	Total comprehensive income for the period/ year (9+10)	1,082	583	675	2,483	3,911	4,
12	Profit for the period/year attributable to:						
	Owners of the Company	804	651	627	2,205	3,879	4,
	Non-controlling interests	-	-	7	-	15	
13	Other comprehensive income attributable to:						
	Owners of the Company	278	(68)	41	278	17	
	Non-controlling interests		-	-		-	
	Tet la serie la cherre establista la ter						
4	Total comprehensive income attributable to:	1 092	583	668	2,483	3,896	4,
	Owners of the Company Non-controlling interests	1,082		7	-	15	
	Non-condoning interests						
5	Paid-up equity share capital (face value of ₹2 each)	365	365	364	365	364	
	· · · · · · · · · · · · · · · · · · ·						
	Othersenite						40,
6	Other equity						-10,
17	Earnings per share						
	(face value ₹2 each)		3.57	3.44	12.09	21.30	24
	Basic (in ₹)	4.41					
	Diluted (in ₹)	4.40	3.57	3.43	12.08	21.25	24
		(Non-annualised)	(Non-annualised)	(Non-annualised)	(Non-annualised)	(Non-annualised)	

3

See accompanying notes to the consolidated financial results.



NATCO Pharma Limited

			Quarter ended			Nine Months ended	
C M	Particulars	31 December 2021	30 September 2021	31 December 2020	31 December 2021	31 December 2020	Year ended 31 March 2021
S.No.	Particulars	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment revenue						
	a. Pharmaceuticals	5,602	3,738	3,545	13,437	17,200	20,500
	b. Agro chemicals	3	34	7	43	8	21
		5,605	3,772	3,552	13,480	17,208	20,521
	Add: Unallocated	-	-	-	-	-	-
	Total revenue from operations	5,605	3,772	3,552	13,480	17,208	20,521
2	Segment results						
	a. Pharmaceuticals	1,060	811	833	2,820	5,189	5,941
	b. Agro chemicals	(100)	(73)	2	(192)	(2)	(12)
	Total segment result	960	738	835	2,628	5,187	5,929
	Less:						
	a. Finance cost	(50)	(40)	(34)	(110)	(98)	(133)
	b. Net unallocated (income)/expenditure	-	-	-	-	-	-
	Total profit before tax	910	698	801	2,518	5,089	5,796
3	Segment assets						
	a. Pharmaceuticals	44,808	43,392	43,513	44,808	43,513	42,452
	b. Agro chemicals	3,321	3,162	2,179	3,321	2,179	2,393
	Total segment assets	48,129	46,554	45,692	48,129	45,692	44,845
	Add:						
	a. Unallocated	3,187	3,963	2,639	3,187	2,639	3,074
	Total assets	51,316	50,517	48,331	51,316	48,331	47,919
4	Segment liabilities						
	a. Pharmaceuticals	4,171	4,005	3,799	4,171	3,799	3,499
	b. Agro chemicals	42	95	77	42	77	84
	Total segment liabilities	4,213	4,100	3,876	4,213	3,876	3,583
	Add:						
	a. Unallocated	3,821	4,130	3,639	3,821	3,639	3,102
	Total liabilities	8,034	8,230	7,515	8,034	7,515	6,685

200



Notes to unaudited consolidated financial results:

- The unaudited consolidated financial results of NATCO Pharma Limited ("the Company") and its subsidiaries (together referred as "the Group") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The unaudited consolidated financial results for the quarter and nine months ended 31 December 2021 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 14 February 2022.
- 3) The results of the Group for the quarter and nine months ended 31 December 2021, have been reviewed by the statutory auditors and they have issued an unqualified review report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) The consolidated financial results for the quarter and nine months ended 31 December 2021 include financial results of the following subsidiaries:

Sr. No	Name of the Entity
1	NATCO Pharma Inc., United States of America
2	Time Cap Overseas Limited, Mauritius
3	NATCO Farma do Brasil Ltda, Brazil (subsidiary of Time Cap Overseas Limited)
4	NATCO Pharma (Canada) Inc., Canada
5	NATCO Pharma Asia Pte. Ltd., Singapore
6	NATCO Pharma Australia PTY Ltd., Australia
7	NATCO Lifesciences Philippines Inc., Philippines

- 5) Revenue from operations includes an income from settlement of claims received by NATCO Pharma (Canada) Inc., Canada a subsidiary of NATCO Pharma Limited under a settlement agreement entered by the subsidiary.
- 6) Based on the most recent forecasts as prepared by the Management, it is expected that the unrecognised MAT credit as at 31 March 2021 will be completely utilised over next five years. Accordindly, effective tax rate of the Group is expected to be comparatively lower in the current year.
- 7) During the nine months ended 31 December 2021, 27,340 equity shares of ₹ 2 each, fully-paid up, were allotted upon exercise of the vested stock options pursuant to the ESOP 2016 scheme resulting in an increase in the paid-up share capital of ₹ 0.05 million and securities premium account of ₹ 16.71 million.
- 8) Subsequent to 31 December 2021, NATCO Pharma Limited through its wholly owned subsidiary, NATCO Pharma Inc. USA, has acquired Dash Pharmaceuticals LLC ("Dash"), a New Jersey based entity for a consideration of USD 18 million. Pursuant to this, Dash has become a 100% wholly owned subsidiary of NATCO Pharma Inc. and a step-down subsidiary of NATCO Pharma Limited.
- 9) The Group has considered internal and external sources of information while assessing the recoverability of its assets up to the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Group expects to recover the carrying amount of these assets. The Board of Directors has also considered the impact of COVID-19 on the business for the foreseeable future and have concluded that the Group has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions.
- 10) The unaudited standalone financial results, for the quarter and nine months ended 31 December 2021 can be viewed on the website of the Company, NSE and BSE at <u>www.natcopharma.co.in</u>, <u>www.nseindia.com</u>, and <u>www.bseindia.com</u> respectively. Information of audited standalone financial results of the Company in terms of Regulation 47(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as under:

Particulars		Quarter ended		Nine Mor	Year ended	
Farticulars	31 December 2021	30 September 2021	31 December 2020	31 December 2021	31 December 2020	31 March 2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total revenue from operations	5,295	3,304	3,309	12,537	13,420	16,535
Profit before tax	797	523	707	2,230	3,188	3,922
Net profit for the period/ year	716	536	547	2,004	2,523	3,095
Total comprehensive income	1,020	513	551	2,372	2,593	3,228

- 11) The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Group will asses the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- 12) The Board of Directors in their meeting held on 14 February 2022 have recommended an interim dividend of ₹ 2 per equity share of ₹ 2 each for the quarter and nine months ended 31 December 2021.

Place: Hyderabad Date: 14 Febreuary 2022

By order of the Board For NATCO Pharma Limited 4

V C Nannapaneni

Chairman and Managing Director (DIN: 00183315)

BSR& Associates LLP

Chartered Accountants

Salarpuria Knowledge City, Orwell, B Wing, 6th Floor, Unit-3, Sy No. 83/1, Plot No. 02, Raidurg, Hyderabad – 500 081 - India Telephone: +91 40 7182 2000 Fax: +91 40 7182 2399

Limited Review Report on unaudited consolidated financial results of NATCO Pharma Limited for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of NATCO Pharma Limited

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of NATCO Pharma Limited ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
- 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the entity	Relationship
NATCO Pharma Limited	Parent
NATCO Pharma, Inc.	Subsidiary
Time Cap Overseas Limited	Subsidiary
NATCO Farma Do Brasil Ltda. (subsidiary of Time Cap Overseas Limited)	Step-down Subsidiary
NATCO Pharma (Canada) Inc.	Subsidiary
NATCO Pharma Asia Pte. Ltd.	Subsidiary



B S R & Associates (a partnership firm with Registration No. BA69226) converted into B S R & Associates LLP (a Limited Liability Partnership with LLP Registration No. AAB-8182) with effect from October 14, 2013 Registered Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

B S R & Associates LLP

NATCO Pharma Australia PTY Ltd.	Subsidiary
NATCO Lifesciences Philippines Inc.	Subsidiary

- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We did not review the interim financial information of seven subsidiaries included in the Statement, whose interim financial information reflect (before consolidation adjustments) total revenues of INR 489.78 million and INR 1,460.49 million, total net profit after tax of INR 88.35 million and INR 204.83 million and total comprehensive income of INR 88.34 million and INR 205.68 million, for the quarter ended 31 December 2021 and for the period from 01 April 2021 to 31 December 2021 respectively, as considered in the unaudited consolidated financial results. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

These subsidiaries are located outside India whose interim financial information and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's management has converted the interim financial information of such subsidiaries located outside India from accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Parent's management. Our opinion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the reports of other auditors and the conversion adjustments prepared by the management of the Parent and reviewed by us.

Our conclusion is not modified in respect of the above matters.

For **B S R & Associates LLP** Chartered Accountants Firm's Registration No.:116231W/W-100024

likast soman

Vikash Somani Partner Membership No.: 061272 UDIN:22061272ABYDJJ2338

Hyderabad 14 February 2022




NATCO Pharma Limited Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034 Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2021

			Quarter ended		Nine Months ended		Year ended	
S.No.	Particulars	31 December 2021	30 September 2021	31 December 2020	31 December 2021	31 December 2020	31 March 2021	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
	Income							
1	Revenue from operations	5,295	3,304	3,309	12,537	13,420	16,535	
2	Other income	316	403	249	842	720	1,011	
3	Total income (1+2)	5,611	3,707	3,558	13,379	14,140	17,546	
4	Expenses							
	Cost of materials consumed	1,006	1,156	756	3,261	2,836	3,729	
	Purchases of stock-in-trade	44	64	220	166	1,721	1,740	
	Changes in inventories of finished goods,		(187 D		121012			
	work-in-progress and stock-in-trade	(109)	(331)	(202)	(792)	(105)	(469)	
	Employee benefits expense	1,116	1,028	958	3,115	2,906	3,800	
	Finance costs	41	32	30	91	90	113	
	Depreciation and amortisation expense	355	342	294	1,028	854	1,152	
	Other expenses	2,361	893	795	4,280	2,650	3,559	
	Total expenses	4,814	3,184	2,851	11,149	10,952	13,624	
	Profit before exceptional items and tax (3-4)	797	523	707	2,230	3,188	3,922	
	Exceptional items Profit before tax (5-6)	- 797	- 523	- 707	2,230	- 3,188	-	
1	Profit before tax (5-6)	191	525	/0/	2,230	3,188	3,922	
8	Tax expense							
	(i) Current tax	142	100	70	397	690	863	
	(ii) Income-tax for earlier years		-	-	-	-	70	
	(ii) Deferred tax (credit)/ charge (refer note 5)	(61)	(113)	90	(171)	(25)	(106)	
	Total tax expense	81	(13)	160	226	665	827	
9	Profit for the period/ year (7-8)	716	536	547	2,004	2,523	3,095	
10	Other comprehensive income (net of tax)						2	
	Items that will not be reclassified to profit or loss:							
	Remeasurement of defined benefit plans	(2)	(2)	(20)	(6)	(59)	(8)	
	Net gains/ (losses) from investments in equity instruments	335	(24)	25	411	144	153	
	designated at FVTOCI		(24)	25	411		155	
	Income-tax relating to items that will not be reclassified to profit or loss	(29)	3	(1)	(37)	(15)	(12)	
	Total other comprehensive income (net of tax)	304	(23)	4	368	70	133	
11	Total comprehensive income for the period/year (9+10)	1,020	513	551	2,372	2,593	3,228	
12	Paid-up equity share capital (face value of ₹2 each)	365	365	364	365	364	365	
13	Other equity						40,546	
14	Earnings per share							
	(face value ₹2 each)						10	
	Basic (in ₹)	3.93	2.94	3.00	10.99	13.85	16.99	
	Diluted (in ₹)	3.92	2.94	3.00	10.98	13.82	16.96	
		(Non-annualised)	(Non-annualised)	(Non-annualised)	(Non-annualised)	(Non-annualised)		

See accompanying notes to the standalone financial results.





NATCO Pharma Limited

Notes to the unaudited standalone financial results:

- The standalone financial results of NATCO Pharma Limited ("the Company") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The standalone financial results for the quarter and nine months ended 31 December 2021 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 14 February 2022.
- 3) The results of the Company for the quarter and nine months ended 31 December 2021, have been reviewed by the statutory auditors and they have issued an unqualified review report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) Where financial results contain both consolidated and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the consolidated financial results.
- 5) Based on the most recent forecasts as prepared by the Management, it is expected that the unrecognised MAT credit as at 31 March 2021 will be completely utilised over next five years. Accordindly, effective tax rate of the Company is expected to be comparatively lower in the current year.
- 6) During the nine months ended 31 December 2021, 27,340 equity shares of ₹ 2 each, fully-paid up, were allotted upon exercise of the vested stock options pursuant to the ESOP 2016 scheme resulting in an increase in the paid-up share capital of ₹ 0.05 million and securities premium account of ₹ 16.71 million.
- 7) Subsequent to 31 December 2021, NATCO Pharma Limited through its wholly owned subsidiary, NATCO Pharma Inc. USA, has acquired Dash Pharmaceuticals LLC ("Dash"), a New Jersey based entity for a consideration of USD 18 million. Pursuant to this, Dash has become a 100% wholly owned subsidiary of NATCO Pharma Inc. and a step-down subsidiary of NATCO Pharma Limited.
- 8) The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will asses the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- 9) The Company has considered internal and external sources of information while assessing the recoverability of its assets upto the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Company expects to recover the carrying amount of these assets. The Board of Directors has also considered the impact of COVID-19 on the business for the foreseeable future and have concluded that the Company has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions.
- 10) The Board of Directors at their meeting held on 14 February 2022 have recommended an interim dividend of ₹ 2 per equity share of ₹ 2 each for the quarter and nine months ended 31 December 2021.

By order of the Board For NATCO Pharma Limited

٤ V C Nannapanen Chairman and Managing Director (DIN: 00183315)

Place: Hyderabad Date: 14 February 2022

BSR& Associates LLP

Chartered Accountants

Salarpuria Knowledge City, Orwell, B Wing, 6th Floor, Unit-3, Sy No. 83/1, Plot No. 02, Raidurg, Hyderabad – 500 081 - India Telephone: +91 40 7182 2000 Fax: +91 40 7182 2399

Limited Review Report on unaudited standalone financial results of NATCO Pharma Limited for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of NATCO Pharma Limited

- 1. We have reviewed the accompanying Statement of unaudited standalone financial results of NATCO Pharma Limited ("the Company") for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 ("the Statement").
- 2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Associates LLP** Chartered Accountants Firm's Registration No.:116231W/W-100024,

likase soma

Vikash Somani Partner Membership No.: 061272 UDIN:22061272ABYCGV6956

Hyderabad 14 February 2022

B S R & Associates (a partnership firm with Registration No. BA59226) converted into B S R & Associates LLP (a Limited Liability Partnership with LLP Registration No. AAB-81B2) with effect from October 14, 2013

Registered Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Annexure

Brief Profile of Working Directors

Particulars	Sri V C Nannapaneni	Sri Rajeev Nannapaneni	Sri P S R K Prasad	Dr. D Linga Rao
Reasons for Change	appointment	appointment	Re- appointment	Re- appointment
Date of Appointment &	Upon the recommendation of	Upon the recommendation of	Upon the recommendation of	Upon the recommendation o
Term of Appointment	Nomination and Remuneration	Nomination and Remuneration	Nomination and Remuneration	Nomination and Remuneration
	Committee, the Board of Directors	Committee, the Board of Directors at	Committee, the Board of Directors	Committee, the Board of Director
	at their meeting held on 14 th	their meeting held on 14th February	at their meeting held on 14 th	at their meeting held on 14t
	February 2022 have appointed Sri	2022 have appointed Sri Rajeev	February 2022 have reappointed	February 2022 have reappointed D
	V C Nannapaneni subject to	Nannapaneni subject to approval of	Sri P S R K Prasad subject to approval	D Linga Rao subject to approval of
	approval of members at the ensuing	members at the ensuing Annual	of members at the ensuing Annual	members at the ensuing Annua
	Annual General Meeting	General Meeting	General Meeting	General Meeting
1.4	Term of Appointment:	Term of Appointment:	Term of Appointment:	Term of Appointment:
	Period: 1 st April 2022 to 31 st	Period: 1 st April 2022 to 31 st	Period: 1 st April 2022 to 31 st	Period: 1 st April 2022 to 31 st
	March, 2024	March, 2024	March, 2024	March, 2024
Brief Profile of the	Sri V.C. Nannapaneni, Managing	Sri Rajeev Nannapaneni, Chief	Sri P.S.R.K. Prasad, Director and	Dr. D. Linga Rao, Director and
Directors	Director is associated with the	Executive Officer is associated	Executive Vice President	President (Technical Affairs) ha
	Company as founder/promoter	with the Company for the past 22	Corporate Engineering Services)	more than 41 years o
	and driving the Company	years and he is taking care of all	is associated with the Company	experience in pharmaceutica
	towards higher growths. He is	the functional operations of the	for the past 27 years.	industry and has been working
	taking care of new product	Company including but not limited	He has got good knowledge in	with the Company for over 2
	developments and their launch,	to Production, Finance, Legal &	procuring right equipment(s)	years. He has vast experience i
	overall guidance in clinical trails	Secretarial, new drug launches,	and machinery for production	various departments like R&D
	and R&D.	Domestic and International	processes and to provide all	Quality Control, Qualit
		Marketing, etc.	utility services and to utilize the	Assurance and
		Marketing, etc.		Regulatory affairs.
			and a second sec	Regulatory allalis.
			material in an optimum way and	
			to ensure safety of life and	
			property.	
Disclosure relationships Directors (In case of appointment Directors)	Father of Rajeev Nannapaneni	Son of Sri V C Nannapaneni	NIL	NIL

×

Jutalay and



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/23/2021-2022

Press Release

Hyderabad, 14th February, 2022

NATCO records INR 590.7 Crore consolidated revenue and INR 80.4 Crore of profit, after tax, for the Third Quarter, FY2021-22

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR 590.7 Crore, including product licensing income, for the Third quarter ended on 31st December, 2021, as against INR 386.0 Crore for the same period last year, reflecting a 53% increase in revenue. The net profit for the period, on a consolidated basis, was INR 80.4 Crores as against INR 63.40 Crore same period last year, with increase of 27% in net profits. During the quarter, there was a one-time expense against product licensing income.

Segmental Revenue Split (All Figures in INR Crore)-

Segment	Revenue, Q3 FY22
API	61.7
Formulations, Domestic	100.3
Formulations, Exports (incl. Profit Share, Licensing Inc & Foreign Subs)	383.1
Other Operating income & non-operating income	45.3
Crop Health Sciences (CHS)	0.3

The Board of Directors has recommended Third interim dividend of INR 2.0 per equity share of INR 2.0 each, for FY 2021-22.

Forwarded for favor of publication For NATCO Pharma Limited

MAwaren

M Adinarayana Company Secretary & Vice President (Legal & Corp Affairs)